CTLA4 and colitis: An increase in serum IL-17 levels was demonstrated following CTLA-4 blockade with ipilimumab in patients developing colitis, consistent with CTLA-4 inhibiting the production of IL-17 by type 17 T helper (Th17) cells [101,102].